Antivascular	B-Multi-tissue_structure
actions	O
of	O
microtubule	B-Cellular_component
-	O
binding	O
drugs	O
.	O

Microtubule	B-Cellular_component
-	O
binding	O
drugs	O
(	O
MBD	O
)	O
are	O
widely	O
used	O
in	O
cancer	B-Cancer
chemotherapy	O
and	O
also	O
have	O
clinically	O
relevant	O
antiangiogenic	O
and	O
vascular	B-Multi-tissue_structure
-	O
disrupting	O
properties	O
.	O

These	O
antivascular	B-Multi-tissue_structure
actions	O
are	O
due	O
in	O
part	O
to	O
direct	O
effects	O
on	O
endothelial	B-Cell
cells	I-Cell
,	O
and	O
all	O
MBDs	O
(	O
both	O
microtubule	B-Cellular_component
-	O
stabilizing	O
and	O
microtubule	B-Cellular_component
-	O
destabilizing	O
)	O
inhibit	O
endothelial	B-Cell
cell	I-Cell
proliferation	O
,	O
migration	O
,	O
and	O
tube	B-Tissue
formation	O
in	O
vitro	O
,	O
actions	O
that	O
are	O
thought	O
to	O
correspond	O
to	O
therapeutic	O
antiangiogenic	O
actions	O
.	O

In	O
addition	O
,	O
the	O
microtubule	B-Cellular_component
-	O
destabilizing	O
agents	O
cause	O
prominent	O
changes	O
in	O
endothelial	B-Cell
cell	I-Cell
morphology	O
,	O
an	O
action	O
associated	O
with	O
rapid	O
vascular	B-Multi-tissue_structure
collapse	O
in	O
vivo	O
.	O

The	O
effects	O
on	O
endothelial	B-Cell
cells	I-Cell
occur	O
in	O
vitro	O
at	O
low	O
drug	O
concentrations	O
,	O
which	O
do	O
not	O
affect	O
microtubule	B-Cellular_component
gross	O
morphology	O
,	O
do	O
not	O
cause	O
microtubule	B-Cellular_component
bundling	O
or	O
microtubule	B-Cellular_component
loss	O
and	O
do	O
not	O
induce	O
cell	B-Cell
cycle	O
arrest	O
,	O
apoptosis	O
,	O
or	O
cell	B-Cell
death	O
.	O

Rather	O
,	O
it	O
has	O
been	O
hypothesized	O
that	O
,	O
at	O
low	O
concentrations	O
,	O
MBDs	O
produce	O
more	O
subtle	O
effects	O
on	O
microtubule	B-Cellular_component
dynamics	O
,	O
block	O
critical	O
cell	B-Cell
signaling	O
pathways	O
,	O
and	O
prevent	O
the	O
microtubules	B-Cellular_component
from	O
properly	O
interacting	O
with	O
transient	O
subcellular	B-Cellular_component
assemblies	I-Cellular_component
(	O
focal	B-Cellular_component
adhesions	I-Cellular_component
and	O
adherens	B-Cellular_component
junctions	I-Cellular_component
)	O
whose	O
subsequent	O
stabilization	O
and	O
/	O
or	O
maturation	O
are	O
required	O
for	O
cell	B-Cell
motility	O
and	O
cell	B-Cell
-	O
cell	B-Cell
interactions	O
.	O

This	O
review	O
will	O
focus	O
on	O
recent	O
studies	O
to	O
define	O
the	O
molecular	O
mechanisms	O
for	O
the	O
antivascular	B-Multi-tissue_structure
actions	O
of	O
the	O
MBDs	O
,	O
information	O
that	O
could	O
be	O
useful	O
in	O
the	O
identification	O
or	O
design	O
of	O
agents	O
whose	O
actions	O
more	O
selectively	O
target	O
the	O
tumor	B-Multi-tissue_structure
vasculature	I-Multi-tissue_structure
.	O

